Iovance Biotherapeutics, INC Form 4 insider transactions

Daniel Gordon Kirby, Chief Commercial Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on August 10, 2026.

Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on August 6, 2026.

IOVA Director Michael Weiser reported the grant of 90,316 Deferred Restricted Stock Units (DRSUs) on June 16, 2026, with vesting contingent on continued service and issuance deferred until specific events.

Iain Dukes, a Director at IOVANCE BIOTHERAPEUTICS, INC., acquired 180,632 Deferred Restricted Stock Units on June 16, 2026.

IOVA Director Athena Countouriotis has reported the grant of 90,316 Deferred Restricted Stock Units (DRSUs) under the company's equity incentive plan.

IOVANCE BIOTHERAPEUTICS, INC. Director Ryan Maynard was granted 90,316 Deferred Restricted Stock Units (DRSUs) on June 16, 2026, with vesting and issuance subject to service and specific future events.

Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC., was granted 15,000 restricted stock units on June 16, 2026, vesting over three years.

Interim CEO and General Counsel Frederick G. Vogt acquired 15,625 shares of Iovance Biotherapeutics common stock via RSU vesting.

Chief Medical Officer Friedrich Graf Finckenstein acquired 7,813 shares of Iovance Biotherapeutics via RSU vesting, with 3,976 shares withheld for taxes.

Chief Regulatory Officer Raj K. Puri acquired 9,766 shares of Iovance Biotherapeutics via RSU vesting, with a portion withheld for taxes.

Iovance Biotherapeutics Chief Operating Officer Igor Bilinsky acquired 7,813 shares via RSU vesting, with 3,976 shares withheld for taxes.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, Inc., reported transactions involving restricted stock units and common stock.

Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC., reported the vesting of 5,469 Restricted Stock Units (RSUs) and the subsequent withholding of 2,508 shares for tax purposes on June 1, 2026.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, Inc., acquired 8,790 shares of common stock through the vesting of Restricted Stock Units.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc., reported transactions involving restricted stock units and common stock.

Iovance Biotherapeutics Chief Commercial Officer Daniel Kirby acquired 10,000 shares through RSU vesting, with a portion withheld for taxes.

IOVANCE BIOTHERAPEUTICS' Interim CEO & General Counsel, Frederick G. Vogt, reported the vesting of 62,493 Restricted Stock Units and subsequent tax withholding.

Iovance Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported the vesting of 31,246 restricted stock units and subsequent tax withholding.

IOVANCE BIOTHERAPEUTICS' Chief Regulatory Officer, Raj K. Puri, reported the vesting of 39,059 restricted stock units and subsequent share withholding for tax obligations.

IOVANCE BIOTHERAPEUTICS' Chief Operating Officer, Igor Bilinsky, reported the vesting of 31,246 restricted stock units and the subsequent withholding of 16,628 shares for tax obligations.

IOVANCE BIOTHERAPEUTICS' Interim CEO, Frederick G. Vogt, reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent share disposition for tax obligations.

IOVANCE BIOTHERAPEUTICS' Chief Regulatory Officer, Raj K. Puri, reported the vesting of 5,470 restricted stock units and a subsequent sale of 2,798 shares to cover tax obligations.

IOVANCE Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported the vesting of restricted stock units and subsequent tax-related share withholding.

IOVANCE BIOTHERAPEUTICS' Chief Commercial Officer, Daniel Gordon Kirby, vested 120,000 performance-based restricted stock units, with a portion withheld for tax obligations.

IOVANCE BIOTHERAPEUTICS' Chief Commercial Officer, Daniel Gordon Kirby, reported the vesting of restricted stock units and subsequent tax-related share withholding.

IOVANCE Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported the vesting of restricted stock units and subsequent share disposals for tax obligations in early December 2025.

IOVANCE BIOTHERAPEUTICS Chief Operating Officer Igor Bilinsky reported the vesting of restricted stock units and subsequent share disposals for tax withholding on December 1 and 2, 2025.

IOVANCE BIOTHERAPEUTICS' Interim CEO, Frederick G. Vogt, reported the vesting of restricted stock units and subsequent share withholding for tax obligations on December 1 and 2, 2025.

IOVANCE BIOTHERAPEUTICS' Chief Regulatory Officer, Raj K. Puri, reported the vesting of 5,469 restricted stock units and the subsequent withholding of 2,467 shares for tax obligations.